secwatch.observer — SEC 8-K summary
======================================

Issuer:     Verrica Pharmaceuticals Inc. (VRCA)
CIK:        0001660334
Form:       8-K
Filed at:   2026-03-11T23:59:59+00:00
Accession:  0001193125-26-101126
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Verrica Q4 2025: YCANTH net revenue up 130% to $15.3M; total revenue $35.6M
---------------------------------------------------------------------------

- Q4 product revenue $3.7M vs $0.3M YoY; total revenue $35.6M in 2025, up from $7.6M in 2024.
- YCANTH dispensed units up 99% to 51,296 in 2025; SG&A cut by over 40% to $35.2M.
- Net loss $17.9M ($1.68/share) for full year 2025 vs $76.6M ($14.78/share) in 2024.
- Company has no outstanding debt; cash runway extended into Q1 2027.
- Phase 3 for common warts initiated; VP-315 advancing to Phase 3 for basal cell carcinoma.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1660334/000119312526101126/0001193125-26-101126-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1660334/000119312526101126/d94203d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-101126

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer